A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
about
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerThe imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsiaAngiogenic factors in preeclampsia: potential for diagnosis and treatmentFirst-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Yi qi qing re gao attenuates podocyte injury and inhibits vascular endothelial growth factor overexpression in puromycin aminonucleoside rat model.New developments in the pathogenesis of preeclampsiaBevacizumab increases risk for severe proteinuria in cancer patients.Renal involvement in preeclampsia: similarities to VEGF ablation therapyPreeclampsia and the Anti-Angiogenic StateEvaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.Mechanism of kidney injury caused by bevacizumab in ratsRelevance of VEGF and nephrin expression in glomerular diseases.Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.Nephrotoxicity of recent anti-cancer agents.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewCardiotoxicity of molecularly targeted agentsManagement of antiangiogenic therapy-induced hypertension.The case / progressive hypertension and proteinuria on anti-angiogenic therapyIs VEGF a new therapeutic target for hypertension in chronic kidney disease?Angiogenic factors in preeclampsia and related disordersPreeclampsia, gestational hypertension and subsequent hypothyroidism.Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.VEGF inhibition, hypertension, and renal toxicityRegulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapiesRenal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors.Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factorDevelopment of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma.Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.The adverse effects of sorafenib in patients with advanced cancers.Onco-nephrology: current concepts and future perspectives.Anti-angiogenesis and Preeclampsia in 2016.Nephrotoxicity of anticancer treatment.Sunitinib induced nephrotic syndrome and thrombotic microangiopathy.
P2860
Q24595773-D85AD1E7-8B5D-416B-A3C2-C63116BFEC10Q26798193-711F4060-B038-4D22-AF3D-90BDF865DB2DQ26825774-EE19BDF1-F192-4656-B3A9-818F524EB9B3Q28537681-7A2B603C-CB73-4C3A-BA75-0EF9B6894BD5Q33423350-D3F9FC6D-C0B7-4E9D-8C0F-5EE89D7CCF15Q33684042-5C37150B-FAF7-4170-83DF-815BD923CBB7Q33748334-E7AC0DA1-9BC4-45B5-82AF-B791DAFB9369Q33935675-E9E4BF3A-FEF2-419B-AD7C-E87228B0B2C2Q34124173-E8A7C2B7-71FA-44FE-AC69-F07B5A997F36Q34735646-E2D6476B-4B7A-4D77-B863-51F6FC658D50Q34920271-FC953907-95AC-4631-96A9-14AB5BC81ABBQ35002540-3C404754-F174-465B-83A1-E670A2CAF886Q35038600-1767BC0A-FFBC-4FFC-96BA-B5642BAD5255Q35131059-1FF82FE6-1A8A-4455-9D59-6F52578272B4Q35143007-B81B5F1D-E411-4DAD-925E-5850E83A27B1Q35295368-BE5CE72D-0346-46BD-B9F2-BD5480F4CEA3Q35310741-188DFFD8-D5A1-4C29-A9AB-2A4896348802Q35584543-76CB8CF7-4D69-4A61-B016-4E033A7E9472Q35878459-8D53762C-E6B2-48E1-BF62-4F5DD2FF9CB0Q36170252-32FE5C5E-8038-4504-8254-7071D8CEB5E5Q36213442-E06EA03B-98A9-423C-9C90-F1C4CC693551Q36465668-D46BD158-D4D9-4500-B75D-D1E691EF5F71Q36526596-E08B3C71-B754-4033-A4E5-115AC8BF00C7Q36627811-86E8F688-AF8E-4D82-A1FD-A6B8262911FEQ36891574-ABD003D0-5BFD-49D6-8246-9894B2EDD9A2Q37103555-7816BFC7-D16A-4742-B0E3-E8D851BE9A8CQ37385797-18BE8583-A7A8-4EF2-B37F-F4E6391B87B4Q37598818-0FDFF280-7621-4B46-8F7F-FE7D6EFC33DEQ37632878-C77835A3-1017-4B34-A8C6-E9E0DD5FD3B8Q37670305-01F3A8FD-CAA6-4A98-8A78-BD1F108FEA77Q37946895-B2482564-C70D-489D-9A69-E25985D242A2Q37957052-440C76D5-EEE1-438F-88BA-FD58C8273409Q38068497-3EABCCAD-8317-4E6E-A9F7-BD678B5C5886Q38103397-01F01477-5281-4781-91A8-F6E6DE475696Q38169098-5A0629AE-B63C-4B7B-AF22-5923B1A7A20DQ38286308-E0378AA7-38AB-46E9-AA45-358A7ED82E99Q38382457-C7DD90FA-F04E-4E2C-9CB9-2F7311ACB310Q39117000-06F5F80E-59B2-4FBB-AE23-B8A9CEB86B3BQ39198933-114BAEE6-21B3-4BF4-998D-FC30589CE2C0Q39712982-C083A39C-E48D-49CC-B9F5-E987870F8AD2
P2860
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@en
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@nl
type
label
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@en
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@nl
prefLabel
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@en
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@nl
P2093
P356
P1476
A preeclampsia-like syndrome c ...... itors sunitinib and sorafenib.
@en
P2093
Benjamin D Humphreys
George D Demetri
Jeffrey A Morgan
Michael Quigley
Suzanne George
Tejas V Patel
P304
P356
10.1093/JNCI/DJM311
P407
P577
2008-02-12T00:00:00Z